Found 2030 results for "cancer"
Pulmonary nodules are among the most common incidental findings on chest imaging, yet determining whether they are benign or malignant without invasive biopsy…
A previously unrecognized molecular mechanism in an aggressive blood cancer subtype may open a new class of therapeutic targets — one that challenges a…
How sedentary time is structured — not just its total duration — may matter as much as how much time is spent sitting overall. This large-scale finding…
For the roughly 15–20% of breast cancer patients whose tumors resist standard chemotherapy, the search for viable alternatives has long been hampered by the…
For the millions of men who undergo prostate cancer surgery each year, a rising PSA after the procedure—known as biochemical recurrence—has long signaled…
As multicancer early detection tests move from laboratory promise toward population-scale deployment, a critical question has gone largely unasked: does…
For men with metastatic castration-resistant prostate cancer, the approval of lutetium-177 PSMA-617 represented a meaningful advance in targeted therapy — but…
For heart transplant patients, the long shadow of immunosuppression doesn't end with rejection prevention — it extends to cancer risk that persists for years…
For cancers that resist nearly every available treatment — glioblastoma, pancreatic ductal adenocarcinoma, metastatic castration-resistant prostate cancer…
One of the most persistent questions in cancer immunotherapy has been whether engineered T cells can sustain long-term surveillance or whether they fade…
For patients with blood cancers that resist standard therapies, the challenge has long been that malignant cells hijack fundamental cellular machinery to…
The blood system is quietly central to how we age. Hematopoietic stem cells (HSCs) orchestrate lifelong immune competence, red blood cell turnover, and clot…
Lung cancer kills more people annually than any other malignancy, and the persistence of drug resistance alongside tumour heterogeneity means that even the…
Ruxolitinib, a clinically approved JAK1/2 inhibitor, administered early and intermittently during radiotherapy suppressed the pro-inflammatory…
For women with dense breasts, the decision to add ultrasound screening on top of a negative mammogram carries real consequences — and a decade of data from…
Understanding why some cancer patients fail to respond to immunotherapy is one of oncology's most pressing puzzles. A newly identified mechanism involving a…
For the roughly 300,000 men diagnosed annually with prostate cancer in the United States alone, the sequencing of treatments has long been dictated by disease…
For children who survive leukemia, the cancer itself may not be the final threat to their health — the treatments that saved their lives can silently damage…
The frontier of cancer immunotherapy is shifting in a way that challenges a long-held assumption: that mRNA technology is primarily a delivery mechanism for…
For the roughly 70% of breast cancers that are estrogen receptor-positive, tamoxifen has been a cornerstone therapy for decades — yet outcomes vary…